Skip to content
OpenCapital
Get started

Lineage Cell Therapeutics LCTX Q1 2026 earnings

Reported May 12, 2026 · After market close

Revenue$1.7MMiss by $1.9MDiluted EPS-$0.03Miss by $0.01
Revenue estimate$3.6M
EPS estimate-$0.02

Next report

Aug 11, 2026 (In 3 weeks)
Revenue estimate$1.8M
EPS estimate-$0.03

Versus estimates

Revenue

Q1 2026$1.7MMiss by $1.9M
Q4 2025$6.6MBeat by $4.6MQ3 2025$3.7MBeat by $1.7MQ2 2025$2.8MBeat by $876.1KQ1 2025$1.5MMiss by $222.3KQ4 2024$2.9MBeat by $1.5M

Diluted EPS

Q1 2026-$0.03Miss by $0.01
Q4 2025$0.00Beat by $0.05Q3 2025-$0.13Miss by $0.11Q2 2025-$0.01Beat by $0.01Q1 2025-$0.02In lineQ4 2024-$0.01Beat by $0.03

Ask the moment Lineage Cell Therapeutics reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Lineage Cell Therapeutics report Q1 2026 earnings?
Lineage Cell Therapeutics (LCTX) reported Q1 2026 earnings on May 12, 2026 after market close.
What were Lineage Cell Therapeutics's Q1 2026 revenue and EPS?
Lineage Cell Therapeutics reported revenue of $1.7M and diluted EPS of $-0.03 for Q1 2026.
Did Lineage Cell Therapeutics beat estimates in Q1 2026?
Revenue missed the consensus estimate of $3.6M by $1.9M. EPS missed the consensus estimate of $-0.02 by $0.01.
How did Lineage Cell Therapeutics's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 14.8% from $1.5M a year earlier and diluted EPS declined 50.0% from $-0.02.
Where can I find Lineage Cell Therapeutics's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-219421) and the 10-Q periodic report (0001193125-26-219479) directly on SEC EDGAR. The filing index links above go to sec.gov.